Form 4 for ATRA Atara Biotherapeutics, Inc.
Accepted 2022-03-03 00:00:00 ET · period of report 2022-03-01 · accession 0001140361-22-007766 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-03 | 2022-03-01 | ATRA | Yarema Kristin | Chief Commercial Off | A - Grant | $0.00 | +45.5K | 171.4K | +36% | $0 |
| D | 2022-03-03 | 2022-03-01 | ATRA | Yarema Kristin | Chief Commercial Off | A - Grant | $0.00 | +85.6K | 85.6K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-01 | A | A | 45,533 | $0.00 | 171,415 | D | — | — | (F1) These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2022, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year. |
| 2 | Derivative | Employee Stock Option (Right to Buy) | 2022-03-01 | A | A | 85,592 | $0.00 | 85,592 | D | $10.21 · — to 2032-02-28 | 85,592 Common Stock | (F2) 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2022, subject to the reporting person's continuous service. |